Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Translational research: are we on the right track?
Charles L. Sawyers
Charles L. Sawyers
Published November 3, 2008
Citation Information: J Clin Invest. 2008;118(11):3798-3801. https://doi.org/10.1172/JCI37557.
View: Text | PDF
ASCI Presidential Address Supplement

Translational research: are we on the right track?

  • Text
  • PDF
Abstract

Authors

Charles L. Sawyers

×

Figure 3

Model of imatinib binding to ABL kinase domain.

Options: View larger image (or click on image) Download as PowerPoint
Model of imatinib binding to ABL kinase domain.
The 2 panels depict wild...
The 2 panels depict wild-type Abl in complex with STI-571 (imatinib; left) and predicted structure of STI-571 binding pocket of T315I mutant Abl in complex with STI-571 (right). In the molecular structures representing STI-571 and Abl residue 315, nitrogen atoms are shown in blue, and oxygen atoms are shown in red. A hydrogen bond between Thr315 (left) and STI-571 is shown by the dashed line. Van der Waals interactions are depicted in gray for STI-571 (both panels), in blue for wild-type Abl residue Thr315 (left), and in red for mutant Abl residue Ile315 (right). The polypeptide backbone of the Abl kinase domain is represented in green. Reprinted with permission from Science.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts